These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24604705)

  • 21. Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin.
    Bertelloni S; Massart F; Einaudi S; Wasniewska M; Miccoli M; Baroncelli GI
    Horm Res Paediatr; 2015; 84(6):396-400. PubMed ID: 26528763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Triptorelin therapy in girls with central precocious puberty increases body mass index].
    Martín Díaz MJ; Soriano Guillén L; Muñoz Calvo MT; Pozo Román J; Argente Oliver J
    An Pediatr (Barc); 2006 Nov; 65(5):428-33. PubMed ID: 17184602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment.
    Arrigo T; De Luca F; Antoniazzi F; Galluzzi F; Iughetti L; Pasquino AM; Salerno MC; Marseglia L; Crisafulli G
    Eur J Pediatr; 2007 Jan; 166(1):73-4. PubMed ID: 16906400
    [No Abstract]   [Full Text] [Related]  

  • 25. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
    Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triptorelin for the treatment of endometriosis.
    Leone Roberti Maggiore U; Scala C; Remorgida V; Venturini PL; Del Deo F; Torella M; Colacurci N; Salvatore S; Ferrari S; Papaleo E; Candiani M; Ferrero S
    Expert Opin Pharmacother; 2014 Jun; 15(8):1153-79. PubMed ID: 24832495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hair loss in children on long-acting gonadotropin-releasing hormone agonist triptorelin treatment.
    Kauschansky A; Lurie R; Ingber A
    Acta Derm Venereol; 1997 Jul; 77(4):333. PubMed ID: 9228240
    [No Abstract]   [Full Text] [Related]  

  • 28. Precocious puberty in children with myelomeningocele: treatment with gonadotropin-releasing hormone analogues.
    Trollmann R; Strehl E; Dörr HG
    Dev Med Child Neurol; 1998 Jan; 40(1):38-43. PubMed ID: 9459215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty.
    Kirkgoz T; Karakoc-Aydiner E; Bugrul F; Yavas Abali Z; Helvacioglu D; Kiykim A; Bilgic Eltan S; Aruci Kasap N; Baris S; Ozen A; Guran T; Bereket A; Turan S
    Horm Res Paediatr; 2020; 93(1):66-72. PubMed ID: 31972562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
    Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.
    Oostdijk W; Drop SL; Odink RJ; Hümmelink R; Partsch CJ; Sippell WG
    Acta Paediatr Scand Suppl; 1991; 372():39-45; discussion 46. PubMed ID: 1833950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment].
    Messaaoui A; Massa G; Tenoutasse S; Heinrichs C
    Rev Med Brux; 2005 Feb; 26(1):27-32. PubMed ID: 15816337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study.
    Lasorella S; Porto R; Iezzi ML; Pistone C; Marseglia GL; Verrotti A; Brambilla I
    Gynecol Endocrinol; 2020 Apr; 36(4):338-340. PubMed ID: 31441342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The side effects of gonadotropin releasing hormone analog (diphereline) in treatment of idiopathic central precocious puberty.
    Karamizadeh Z; Tabebordbar M; Saki F; Karamifar H; Amirhakimi G
    Acta Med Iran; 2013; 51(1):41-6. PubMed ID: 23456583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoimmune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence?
    Krstevska-Konstantinova M; Jancevska A; Gucev Z
    J Pediatr Endocrinol Metab; 2010 Apr; 23(4):403-6. PubMed ID: 20583547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A patient developing anaphylaxis and sensitivity to two different GnRH analogues and a review of literature.
    Ökdemir D; Hatipoğlu N; Akar HH; Gül Ü; Akın L; Tahan F; Kurtoğlu S
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):923-5. PubMed ID: 25719301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Undulating course of precocious puberty].
    Kolmer M; Schulz U; Herkner K; Frisch H; Waldhauser F
    Padiatr Padol; 1991; 26(6):271-4. PubMed ID: 1838804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.